These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12438698)

  • 1. Control of biochemical reactions through supramolecular RING domain self-assembly.
    Kentsis A; Gordon RE; Borden KL
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15404-9. PubMed ID: 12438698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.
    Kentsis A; Dwyer EC; Perez JM; Sharma M; Chen A; Pan ZQ; Borden KL
    J Mol Biol; 2001 Sep; 312(4):609-23. PubMed ID: 11575918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
    Brzovic PS; Keeffe JR; Nishikawa H; Miyamoto K; Fox D; Fukuda M; Ohta T; Klevit R
    Proc Natl Acad Sci U S A; 2003 May; 100(10):5646-51. PubMed ID: 12732733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.
    Baer R; Ludwig T
    Curr Opin Genet Dev; 2002 Feb; 12(1):86-91. PubMed ID: 11790560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
    Brzovic PS; Rajagopal P; Hoyt DW; King MC; Klevit RE
    Nat Struct Biol; 2001 Oct; 8(10):833-7. PubMed ID: 11573085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA.
    Cohen N; Sharma M; Kentsis A; Perez JM; Strudwick S; Borden KL
    EMBO J; 2001 Aug; 20(16):4547-59. PubMed ID: 11500381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
    Hashizume R; Fukuda M; Maeda I; Nishikawa H; Oyake D; Yabuki Y; Ogata H; Ohta T
    J Biol Chem; 2001 May; 276(18):14537-40. PubMed ID: 11278247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a.
    Gu H; Roizman B
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8963-8. PubMed ID: 12855769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
    Boutell C; Sadis S; Everett RD
    J Virol; 2002 Jan; 76(2):841-50. PubMed ID: 11752173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuning BRCA1 and BARD1 activity to investigate RING ubiquitin ligase mechanisms.
    Stewart MD; Duncan ED; Coronado E; DaRosa PA; Pruneda JN; Brzovic PS; Klevit RE
    Protein Sci; 2017 Mar; 26(3):475-483. PubMed ID: 27977889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains.
    Mallery DL; Vandenberg CJ; Hiom K
    EMBO J; 2002 Dec; 21(24):6755-62. PubMed ID: 12485996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.
    Ruffner H; Joazeiro CA; Hemmati D; Hunter T; Verma IM
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5134-9. PubMed ID: 11320250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.
    Lai HK; Borden KL
    Oncogene; 2000 Mar; 19(13):1623-34. PubMed ID: 10763819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein.
    Ayi TC; Tsan JT; Hwang LY; Bowcock AM; Baer R
    Oncogene; 1998 Oct; 17(16):2143-8. PubMed ID: 9798686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RING fingers and B-boxes: zinc-binding protein-protein interaction domains.
    Borden KL
    Biochem Cell Biol; 1998; 76(2-3):351-8. PubMed ID: 9923704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E.
    Volpon L; Osborne MJ; Capul AA; de la Torre JC; Borden KL
    Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5441-6. PubMed ID: 20212144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins.
    Irminger-Finger I; Siegel BD; Leung WC
    Biol Chem; 1999 Feb; 380(2):117-28. PubMed ID: 10195418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
    Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRCA1 C-terminal domain: structure and function.
    Huyton T; Bates PA; Zhang X; Sternberg MJ; Freemont PS
    Mutat Res; 2000 Aug; 460(3-4):319-32. PubMed ID: 10946236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
    Atipairin A; Canyuk B; Ratanaphan A
    Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.